05.18.2023
Prescriptions for buprenorphine now only require a standard DEA registration number. The x-waiver is no longer required for any prescriber to treat patients with buprenorphine for opioid use disorder.
The Medication Access and Training Expansion (MATE) Act, as of June 27, 2023, requires most licensed prescribers who are either renewing or applying for a new controlled substance DEA license to have completed at least 8 hours of opioid or other substance use disorders (SUD) training.
Exceptions include:
-
previously completed training to meet the requirements of the DATA-2000 waiver to prescribe buprenorphine
-
board certified in addiction medicine or addiction psychiatry
For more on this new DEA license renewal requirement, read about the MATE Act.
Opioid/SUD Training Resources:
- MHC On-Demand CME
- Best Practices and Tools for Chronic Pain (1-hour recorded webinar)
- Chronic Pain Management in Primary Care (1-hour recorded webinar)
- Addressing the "5th vital sign": Pain Management Beyond Opioids (1-hour recorded webinar)
- Pain Management Pearls in the Inpatient Setting (1-hour recorded webinar)